Retatrutide Dose-Response: Evidence from Preclinical and Clinical Studies

Overview

Retatrutide (LY3437943) is a single synthetic peptide that simultaneously activates three hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). This triple agonism distinguishes it mechanistically from dual agonists such as tirzepatide (GIPR/GLP-1R) or single agonists such as semaglutide (GLP-1R only).

Because retatrutide acts on three receptors with different dose-response profiles, characterizing how dose influences efficacy and tolerability requires careful examination across multiple trials. The published evidence base spans a phase 1b multiple-ascending-dose study in type 2 diabetes (PMID 36354040), a phase 2 dose-finding trial in obesity (PMID 37366315), a phase 2 trial in type 2 diabetes (PMID 37385280), and ongoing phase 3 programs.

Receptor Pharmacology and the Shape of the Dose-Response Curve

The three target receptors contribute distinct pharmacodynamic effects at different exposure levels. Understanding this receptor hierarchy explains why weight loss continues to increase through the highest doses studied in humans.

flowchart TD
    A["Retatrutide (s.c. weekly dose)"] --> B["Systemic exposure\n~6-day half-life"]
    B --> C["GLP-1R agonism\n(gut, brain, pancreas)"]
    B --> D["GIPR agonism\n(gut, adipose, brain)"]
    B --> E["GCGR agonism\n(liver, adipose, brain)"]
    C --> F["Reduced gastric emptying\nSatiety signaling\nInsulin secretion (glucose-dependent)"]
    D --> G["Insulin potentiation\nAdipose remodeling\nAppetite reduction"]
    E --> H["Hepatic glucose output suppression\nEnergy expenditure\nLipolysis"]
    F --> I["Combined weight loss\nGlycemic improvement"]
    G --> I
    H --> I
    I --> J["Dose-dependent magnitude:\n1 mg: ~8.7% at 48 wk\n4 mg: ~17.1% at 48 wk\n8 mg: ~22.8% at 48 wk\n12 mg: ~24.2% at 48 wk"]

GLP-1R agonism drives satiety, slowed gastric emptying, and glucose-dependent insulin release. GIPR agonism augments insulin secretion and modulates adipose tissue. GCGR agonism raises hepatic glucose output acutely but, when paired with GLP-1R agonism, shifts the net metabolic balance toward increased energy expenditure and lipolysis. The combination across all three receptors appears to produce an additive or synergistic weight loss effect that exceeds what GLP-1R or GIPR/GLP-1R dual agonism achieves at comparable doses.

Phase 1b: Multiple-Ascending-Dose Study in Type 2 Diabetes (NCT04143802)

The first published multiple-dose trial of retatrutide enrolled 72 adults with type 2 diabetes at four US centers (PMID 36354040; The Lancet, 2022). It was a 12-week, double-blind, placebo-controlled study with an active comparator arm (dulaglutide 1.5 mg) and five ascending dose cohorts.

Cohort structure:

• Cohort 1: 0.5 mg once weekly
• Cohort 2: 1.5 mg once weekly
• Cohort 3: 3 mg once weekly
• Cohort 4: 3 mg escalating to 6 mg (3/6 mg)
• Cohort 5: 3 mg escalating to 6 mg, 9 mg, and then 12 mg (3/6/9/12 mg)

Within each cohort, at least nine participants received retatrutide, three received placebo, and one received dulaglutide.

Glycemic Dose-Response at 12 Weeks

Placebo-adjusted reductions in mean daily plasma glucose were significant in the three highest cohorts:

• 3 mg cohort: -2.8 mmol/L (90% CI: -4.63 to -0.94)
• 3/6 mg cohort: -3.1 mmol/L (90% CI: -4.91 to -1.22)
• 3/6/9/12 mg cohort: -2.9 mmol/L (90% CI: -4.70 to -1.01)

Placebo-adjusted standardized HbA1c (sHbA1c) reductions followed the same pattern:

• 3 mg: -1.4% (90% CI: -2.17 to -0.56)
• 3/6 mg: -1.6% (90% CI: -2.37 to -0.75)
• 3/6/9/12 mg: -1.2% (90% CI: -2.05 to -0.45)

Body Weight at 12 Weeks

Placebo-adjusted body weight reductions showed a progressive dose relationship:

• 0.5 mg: modest reduction
• 1.5 mg: intermediate reduction
• 3/6/9/12 mg: up to -8.96 kg (90% CI: -11.16 to -6.75)

Pharmacokinetics were dose-proportional, with a half-life of approximately 6 days, confirming that once-weekly dosing achieves adequate trough concentrations across dose levels.

Phase 2 Obesity Trial (NCT04881760, PMID 37366315)

Design

The pivotal phase 2 dose-finding trial in obesity was published in the New England Journal of Medicine (2023). It enrolled 338 adults with a BMI of 30 or higher, or 27-30 with at least one weight-related condition. Randomization was 2:1:1:1:1:2:2 across seven arms (six active, one placebo). Treatment lasted 48 weeks.

Active dose arms:

Arms D and E differed only in starting dose (2 mg vs. 4 mg) at the same 8 mg maintenance target, allowing a direct within-study comparison of escalation pace on tolerability at identical steady-state exposures.

Weight Loss by Dose at 24 Weeks (Primary Endpoint)

Least-squares mean percentage change from baseline:

Weight Loss by Dose at 48 Weeks (Key Secondary Endpoint)

The weight loss trajectory had not plateaued at 48 weeks, particularly in the 8 mg and 12 mg arms, suggesting that longer treatment would produce further reduction.

Categorical Responder Analysis at 48 Weeks

The proportion of subjects achieving weight loss thresholds showed a steep dose-dependent gradient:

At 8 mg and 12 mg, virtually all participants achieved at least 5% weight loss, and the majority exceeded 15%.

Dose-Escalation Effect on Tolerability

Gastrointestinal adverse events were the predominant safety signal across all retatrutide arms. They were mostly mild-to-moderate. Comparing the 2 mg versus 4 mg starting dose sub-arms at the same 8 mg maintenance target showed that slower titration (2 mg start) produced fewer early GI events without affecting steady-state efficacy. This pharmacodynamic separation of tolerability from efficacy at the same maintenance dose is consistent with the kinetics of GLP-1R-mediated gastric slowing.

Heart rate increased in a dose-dependent manner, peaking around 24 weeks and declining somewhat by 48 weeks. This pattern is also observed with other GLP-1R agonists and likely reflects sympathetic nervous system modulation through central GLP-1R pathways.

Phase 2 Type 2 Diabetes Trial (NCT04867785, PMID 37385280)

Design

A randomized, double-blind, placebo-controlled, active-comparator trial published in The Lancet (2023) enrolled 281 adults with type 2 diabetes (HbA1c 7.0-10.5%) at 42 US centers. Treatment lasted 36 weeks, with the primary endpoint at 24 weeks. Active comparator was dulaglutide 1.5 mg.

Retatrutide arms:

• 0.5 mg once weekly
• 4 mg once weekly (starting dose 2 mg, escalation arm)
• 4 mg once weekly (no escalation)
• 8 mg once weekly (starting dose 2 mg, slow escalation)
• 8 mg once weekly (starting dose 4 mg, fast escalation)
• 12 mg once weekly (starting dose 2 mg, escalation)

HbA1c Dose-Response at 24 Weeks

Least-squares mean changes from baseline:

HbA1c reductions at 8 mg and 12 mg were significantly greater than dulaglutide (p = 0.0019 and p = 0.0002, respectively). The 4 mg arms were numerically similar to dulaglutide 1.5 mg.

Body Weight Dose-Response at 36 Weeks

Weight reductions at 4 mg and above were significantly greater than placebo. All arms at 4 mg or above also significantly outperformed dulaglutide 1.5 mg. No severe hypoglycemia was reported.

The dose-response relationship was steep between 0.5 mg and 8 mg and appeared to approach a plateau between 8 mg and 12 mg in this shorter 36-week follow-up period, a finding that contrasts somewhat with the 48-week obesity trial where 12 mg showed slightly superior weight loss to 8 mg.

Dose-Escalation Strategy and GI Events

GI adverse events occurred in 35% of retatrutide-treated subjects overall, ranging from 13% at 0.5 mg to 50% at 8 mg fast-escalation. The slow-escalation arm at 8 mg (starting 2 mg) produced fewer early GI events than the fast-escalation arm (starting 4 mg) at the same maintenance dose. This mirrors the obesity trial finding: titration pace modulates early tolerability without changing steady-state efficacy.

Preclinical Context: GCGR Agonism and the Energy Expenditure Component

The addition of glucagon receptor agonism to GLP-1R and GIPR agonism is the primary mechanistic distinction between retatrutide and tirzepatide. Understanding how GCGR agonism contributes to the dose-response requires preclinical context.

GCGR activation stimulates hepatic glucose production through gluconeogenesis and glycogenolysis. In isolation, this is counterproductive in type 2 diabetes. However, when combined with GLP-1R agonism, which suppresses hepatic glucose output and stimulates insulin secretion, the net glycemic effect is neutral or slightly beneficial. The additional metabolic contribution of GCGR agonism appears to be increased energy expenditure and lipolysis in adipose tissue.

Preclinical research using retatrutide in mouse models (PMID 40094000, NPJ Metabolic Health and Disease, 2025) demonstrated that triple agonism at the doses used in rodent studies produced a 14-fold reduction in pancreatic tumor volume compared with controls, and a 17-fold reduction in lung cancer volume, with immune microenvironment remodeling. This preclinical work is not directly translatable to human dose-response for metabolic endpoints, but it illustrates that systemic effects at higher exposure levels extend beyond glycemia and weight.

The dose required to achieve meaningful GCGR occupancy alongside GLP-1R and GIPR occupancy is relevant to why the weight loss response continues to rise through 8-12 mg in clinical trials. At 1 mg, GCGR engagement may be sub-threshold; at 4 mg and above, all three receptors likely reach pharmacologically relevant occupancy.

Summary of Dose-Response Parameters Across Published Studies

Key observations across the dataset:

1. The dose-response relationship for body weight is steep between 1 mg and 8 mg and appears to narrow between 8 mg and 12 mg, with overlapping confidence intervals at the two highest doses in the obesity trial at 24 weeks but divergence at 48 weeks.
2. HbA1c reductions are dose-dependent with an apparent threshold at 8-12 mg for maximum effect, exceeding what established GLP-1R agonists achieve at approved doses.
3. GI adverse events are dose-dependent and partially mitigated by slower dose escalation without loss of steady-state efficacy.
4. Heart rate increases are dose-dependent, peak around 24 weeks, and partially regress thereafter.
5. The half-life of approximately 6 days supports once-weekly dosing across the tested dose range.

Ongoing Phase 3 Programs

Phase 3 development (TRIUMPH registry program, NCT listed as NCT06662383 and others) is evaluating retatrutide at the doses carried forward from Phase 2. The TRIUMPH trials include populations with obesity, obstructive sleep apnea, and knee osteoarthritis. Results from these trials will extend the dose-response characterization to longer durations and broader populations. The design rationale and program structure were published in Diabetes, Obesity and Metabolism (2026, PMID 41090431).

This page is a research-educational summary. All data are drawn from published peer-reviewed literature and registered clinical trial records. Nothing here constitutes medical advice or a recommendation for any dose or use of retatrutide.

See also

More on Retatrutide:

• Retatrutide research overview
• Retatrutide: Mechanism of action
• Retatrutide: Clinical & preclinical evidence
• Retatrutide: Safety profile
• Retatrutide: Pharmacokinetics

Related peptide family:

• GLP Family

Pathway context:

• Incretin Axis (GLP-1, GIP)

Head-to-head comparisons:

• Semaglutide vs Retatrutide
• Tirzepatide vs Retatrutide